2024's first quarter has been fruitful for investors.
Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.
Palantir Technologies (PLTR) shares are trading lower Thursday after Brian White, an analyst from Monness, Crespi, Hardt & Co., downgraded the stock to Sell from Neutral. Additionally, White lowered his price target to $20, citing an "excessive" valuation fueled by the AI boom and that he believes "the darkest days of this economic downturn are ahead of us." Yahoo Finance's Josh Lipton and Akiko Fujita breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. Editor's note: This article was written by Angel Smith